NUPAT-07

Nagoya University Pancreatic Tumor Board trial 07 - NUPAT-07

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs041200028

Enrollment

Registered

2020-07-09

Start date

2020-07-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Borderline resectable pancreatic cancer Borderline resectable, pancreatic cancer

Interventions

GnP group Patients will undergo preoperative chemotherapy with 125mg/m2 nab-PTX and 1000 mg/m2 gemcitabine for four weeks. After first course, if the effectivity and safety were acceptable, patients u

D020360, D059248

GnP, preoperative therapy, concurrent radiotherapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Borderline resectable pancreatic cancer 2.Age 20=< and =<79 3.Performance status 0-1

Exclusion criteria

Exclusion criteria: 1.distant metastasis 2.severe drug allergy 3.viable multiple primary cancer 4.gastrointestinal invasion 5.apparent infectious status 6.history of abdominal radiotherapy 7.pregnant or breastfeeding female

Design outcomes

Primary

Measure	Time frame
R0 resection rate	—

Secondary

Measure	Time frame
2-years local recurrence rate, recurrence free survival, overall survival, pathological tumor reduction according to Evans grade, Tumor response defined by RECIST, rate of completion of preoperative therapy, rate of adverse effect, surgical morbidity	—

Contacts

Public ContactHideki Takami

Nagoya University Graduate School of Medicine

takami.hideki.r7@f.mail.nagoya-u.ac.jp+81-52-744-2245

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026